Tositumomab: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

@@ Line 2: / Line 2: @@
 {| class="wikitable" border="1" width="52%" style="text-align:center"
 |-
-!  colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]
+!  colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref>
 |-
 ! Parameter
@@ Line 12: / Line 12: @@
 ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
 ! Tositumomab
-! Ofatumumab
+! 7.6
 ! Rituximab
 ! Ibritumomab
@@ Line 18: / Line 18: @@
 ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
 ! Tositumomab
-! Ofatumumab
+! 167000
 ! Rituximab
 ! Ibritumomab
@@ Line 35: / Line 35: @@
 |-
 ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
-! Tositumomab
+! 64.8
-! Ofatumumab
+! 68
 ! Rituximab
 ! Ibritumomab
@@ Line 42: / Line 42: @@
 ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
 ! Tositumomab
-! Ofatumumab
+! 32939000
 ! Rituximab
 ! Ibritumomab
 |-
 ! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
-! Tositumomab
+! .078
-! Ofatumumab
+! .017
 ! Rituximab
 ! Ibritumomab
@@ Line 60: / Line 60: @@
 ! Dosage (mg)
 ! Tositumomab
-! Ofatumumab
+! 500 (4th Infusion)
 ! Rituximab
 ! Ibritumomab